Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
Authors
Keywords
Vedolizumab, Inflammatory bowel disease, Ulcerative colitis, Crohn’s disease, Real-world effectiveness
Journal
JOURNAL OF GASTROENTEROLOGY
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2018-06-05
DOI
10.1007/s00535-018-1480-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- P453 Pre-operative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease: A systematic review and meta-analysis
- (2018) C Law et al. Journal of Crohns & Colitis
- OP023 A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in moderately to severely active Crohn’s disease (CD)
- (2018) S Danese et al. Journal of Crohns & Colitis
- DOP046 Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s disease: data from the LOVE-CD trial
- (2018) S Berends et al. Journal of Crohns & Colitis
- Vedolizumab does not Increase the Risk of Enteric Infections as Compared to Infliximab: A Retrospective Cohort Study
- (2017) Joseph D. Meserve et al. GASTROENTEROLOGY
- Safety of Vedolizumab use in Patients with Inflammatory Bowel Disease
- (2017) Raina Shivashankar et al. GASTROENTEROLOGY
- Effect of Vedolizumab Dose Escalation on Recapturing Response in Patients with Inflammatory Bowel Disease
- (2017) Raina Shivashankar et al. GASTROENTEROLOGY
- Rates and Predictors of Surgery in Inflammatory Bowel Disease Patients Initiating Vedolizumab Therapy: Results from the Victory Consortium
- (2017) Jenna L. Koliani-Pace et al. GASTROENTEROLOGY
- Vedolizumab Persistence and Tolerability in Special Populations is Similar to other IBD Users
- (2017) Joshua A. Turkeltaub et al. GASTROENTEROLOGY
- Vedolizumab Is Safe and Effective in Elderly Patients with Inflammatory Bowel Disease
- (2017) Udayakumar Navaneethan et al. INFLAMMATORY BOWEL DISEASES
- Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience
- (2017) Uri Kopylov et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
- (2017) Bruce E. Sands et al. INFLAMMATORY BOWEL DISEASES
- P364 A Swedish observational study (SVEAH) on vedolizumab assessing effectiveness and healthcare resource utilization in patients with inflammatory bowel disease
- (2017) C. Eriksson et al. Journal of Crohns & Colitis
- P326 Efficacy of vedolizumab on patient-reported outcomes in ulcerative colitis patients: results from a prospective German observational study
- (2017) C. Schmidt, C. Langbein, R. Atreya, T. Bruns, A. Dignass, K. Ende, J. Hampe, F. Hartmann, M.F. Neurath, J. Maul, J.C. Preiss, R. Schmelz, B. Siegmund, H. Schulze, N. Teich, U. van Arnim, D.medicine Baumgart et al. Journal of Crohns & Colitis
- P525 Effectiveness and safety of vedolizumab in IBD patients: a multicentre experience of “real world data” from the UK
- (2017) M.V. Lenti et al. Journal of Crohns & Colitis
- OP020 Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn's disease
- (2017) A. Gils et al. Journal of Crohns & Colitis
- P470 Comparative effectiveness analysis of flares, hospitalisations, and corticosteroid use among biologic naïve patients with inflammatory bowel disease within 12 months of initiation of vedolizumab or infliximab
- (2017) N. Alam et al. Journal of Crohns & Colitis
- P454 Can calcineurin inhibitors induce a durable remission that is maintained with vedolizumab in IBD?
- (2017) O. Kassim et al. Journal of Crohns & Colitis
- P391 Differential use of vedolizumab in ulcerative colitis and Crohn's disease. Real life results from 2 tertiary referral centres in the United Kingdom
- (2017) N. Kamperidis et al. Journal of Crohns & Colitis
- DOP023 Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium
- (2017) P. Dulai et al. Journal of Crohns & Colitis
- P447 Vedolizumab induces significantly higher endoscopic remission rates at week 16 in ulcerative colitis as compared to Crohn's disease
- (2017) R.W.M. Pauwels et al. Journal of Crohns & Colitis
- P502 Ulcerative colitis patients on vedolizumab lacking response at induction phase continue to improve over the first 6 months of treatment
- (2017) P. Zezos et al. Journal of Crohns & Colitis
- P357 A multi-institutional report of postoperative outcomes in Vedolizumab-Treated patients undergoing major abdominal operations for inflammatory bowel disease
- (2017) A. Lightner et al. Journal of Crohns & Colitis
- P515 Evaluation of treatment persistence of vedolizumab among Finnish inflammatory bowel disease patients in real-life clinical practice (FINVEDO)
- (2017) T. Ylisaukko-oja et al. Journal of Crohns & Colitis
- N805 Do we need to monitor patients after vedolizumab infusion?
- (2017) K. Robinson et al. Journal of Crohns & Colitis
- P227 Outcomes of anti-TNF versus Vedolizumab therapy for ulcerative colitis: the Leeds experience
- (2017) M.V. Lenti et al. Journal of Crohns & Colitis
- P366 The efficacy of vedolizumab for induction of clinical response and remission in anti-TNF naïve patients with inflammatory bowel disease – a multicenter European real world experience
- (2017) U. Kopylov et al. Journal of Crohns & Colitis
- P410 Vedolizumab is safe and effective for IBD, but has no effect on liver biochemistry in patients with concurrent PSC
- (2017) B. Christensen et al. Journal of Crohns & Colitis
- OP012 Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with ulcerative colitis undergoing (procto)colectomy with ileal pouch-anal anastomosis
- (2017) M. Ferrante et al. Journal of Crohns & Colitis
- P514 Combination treatment with vedolizumab and anti-TNF-α in inflammatory bowel disease: safety data
- (2017) L. Buer et al. Journal of Crohns & Colitis
- P416 Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis: the Edinburgh experience
- (2017) N. Plevris et al. Journal of Crohns & Colitis
- DOP025 Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID
- (2017) S. Tadbiri et al. Journal of Crohns & Colitis
- P668 Post-marketing experience of vedolizumab in inflammatory bowel disease: analysis of pneumonia and other respiratory tract infections
- (2017) F. Bhayat et al. Journal of Crohns & Colitis
- P445 Perioperative use of vedolizumab seems not associated with short-term postoperative infectious complications in patients with Crohn's disease undergoing right hemicolectomy with ileocolonic anastomosis
- (2017) N. Schils et al. Journal of Crohns & Colitis
- Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
- (2017) Marcus Harbord et al. Journal of Crohns & Colitis
- Vedolizumab in IBD–Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
- (2017) Tal Engel et al. Journal of Crohns & Colitis
- Clinical and translational outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease receiving vedolizumab
- (2017) K.D. Williamson et al. JOURNAL OF HEPATOLOGY
- Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation
- (2017) Andrew P. Wright et al. LIVER TRANSPLANTATION
- Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
- (2016) D. C. Baumgart et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
- (2016) A. Stallmach et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium
- (2016) Parambir S Dulai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease
- (2016) Aurelien Amiot et al. Clinical Gastroenterology and Hepatology
- Sa1888 Efficacy and Predictors of Outcomes of Vedolizumab for Ulcerative Colitis in Clinical Practice
- (2016) Farhad Peerani et al. GASTROENTEROLOGY
- Tu1908 Safety of Vedolizumab in Inflammatory Bowel Disease in a Multi-Center Real World Consortium
- (2016) Khadija Chaudrey et al. GASTROENTEROLOGY
- Tu1918 Safety of Vedolizumab in Inflammatory Bowel Disease Patients: Real World Experience From a Large University Practice
- (2016) Antonio H. Mendoza Ladd et al. GASTROENTEROLOGY
- Mo1904 Efficacy and Safety of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease
- (2016) Udayakumar Navaneethan et al. GASTROENTEROLOGY
- 812f Efficacy and Safety of Induction Dosing of Vedolizumab for Reducing Biliary Inflammation in Primary Sclerosing Cholangitis (PSC) in Individuals With Inflammatory Bowel Disease
- (2016) Bertus Eksteen et al. GASTROENTEROLOGY
- The safety of vedolizumab for ulcerative colitis and Crohn's disease
- (2016) Jean-Frédéric Colombel et al. GUT
- P-057 Harvey-Bradshaw Index Captures Clinical Efficacy of Vedolizumab Induction Therapy for Active Crohnʼs Disease
- (2016) Meira Abramowitz et al. INFLAMMATORY BOWEL DISEASES
- P-073 YI Single-Center Experience
- (2016) Charoen Mankongpaisarnrung et al. INFLAMMATORY BOWEL DISEASES
- P-025 Hospitalizations and Characteristics of Patients with Ulcerative Colitis and Crohnʼs Disease Treated with Vedolizumab in the United States
- (2016) Matthew Reynolds et al. INFLAMMATORY BOWEL DISEASES
- P-033 YI Efficacy and Safety of Vedolizumab for Inflammatory Bowel Disease in Clinical Practice
- (2016) Khadija Chaudrey et al. INFLAMMATORY BOWEL DISEASES
- Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease
- (2016) Amy L. Lightner et al. Journal of Crohns & Colitis
- An Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
- (2016) Tim Wyant et al. Journal of Crohns & Colitis
- 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
- (2016) Fernando Gomollón et al. Journal of Crohns & Colitis
- Real-World Evidence — What Is It and What Can It Tell Us?
- (2016) Rachel E. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Challenge of Compliance and Persistence: Focus on Ulcerative Colitis
- (2016) Sunanda V. Kane et al. JOURNAL OF MANAGED CARE PHARMACY
- Tu1346 Skin and Joint Side Effects in a Subpopulation of Anti-TNF Experienced IBD Patients, Who Respond to a Treatment With Vedolizumab, a Humanized A4b7 Integrin Antibody
- (2015) Oliver Drvarov et al. GASTROENTEROLOGY
- Tu1359 Efficacy of Vedolizumab As Induction Therapy in Refractory IBD Patients Following Multiple Anti-TNF Therapy Failures
- (2015) Betsy W. Stevens et al. GASTROENTEROLOGY
- Tu1371 A Retrospective Review of Response Rates and Risk of Complications Among Inflammatory Bowel Diseases Patients Treated With Vedolizumab
- (2015) Shannon Oppenheim et al. GASTROENTEROLOGY
- Sa1182 Single-Center Experience of Vedolizumab in Patients With Inflammatory Bowel Disease: Does Age Matter?
- (2015) Bradley Morganstern et al. GASTROENTEROLOGY
- Sa1198 Initial Vedolizumab Cohort: Patient Characteristics and Clinical Response
- (2015) Matthew B. Lucci et al. GASTROENTEROLOGY
- Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients
- (2015) Edward Shelton et al. INFLAMMATORY BOWEL DISEASES
- Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn’s Disease
- (2015) Gionata Fiorino et al. Journal of Crohns & Colitis
- Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice
- (2015) Emily E. Vivio et al. Journal of Crohns & Colitis
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- Geographical variability and environmental risk factors in inflammatory bowel disease
- (2013) Siew C Ng et al. GUT
- Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
- (2013) Laurent Peyrin-Biroulet et al. GUT
- Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
- (2013) Asit Parikh et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population
- (2012) Christina Ha et al. Clinical Gastroenterology and Hepatology
- Therapy of Steroid-Resistant Inflammatory Bowel Disease
- (2012) Michael Manz et al. DIGESTION
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
- (2011) Jean Frédéric Colombel et al. GASTROENTEROLOGY
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
- (2009) D. Soler et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now